Colin Thalhofer, PhD, is a Doctor of immunology.   His immunology training began at the Earle A. Chiles Research Institute, 2000-2003. He went on to the immunology graduate program at the University of Iowa 2003-2011, where his research focused on the molecular and cellular interactions between the protozoan parasite Leishmania and mammalian immune system. 

Colin joined AgonOx Inc. as a researcher in 2013. His primary research is directed toward cancer immunotherapy drug target discovery and development by profiling the cellular and molecular components of the tumor microenvironment.